May 13, 2020 / 9:07 PM / 17 days ago

BRIEF-NGM Biopharmaceuticals Posts Quarterly Loss Per Share $0.28

May 13 (Reuters) - NGM Biopharmaceuticals Inc:

* NGM BIO PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

* $328.5 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2020

* NGM BIOPHARMACEUTICALS - RELATED PARTY REVENUE FROM COLLABORATION WITH MERCK FOR QUARTER ENDED MARCH 31, 2020 WAS $24.4 MILLION

* QTRLY LOSS PER SHARE $0.28

* IMPACT OF COVID-19 PANDEMIC, TO DATE, HAS NOT RESULTED IN A SIGNIFICANT IMPACT TO COMPANY’S DEVELOPMENT TIMELINES

* REMAIN ON TRACK WITH ALL PREVIOUSLY PROVIDED CLINICAL TRIAL TIMING GUIDANCE

* Q1 EARNINGS PER SHARE VIEW $-0.27, REVENUE VIEW $23.0 MILLION — REFINITIV IBES DATA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below